GO
Loading...

Gilead Sciences Inc

More

  • NEW YORK, Dec 22- Equity markets worldwide edged higher on Monday after European energy shares rose, even as oil prices remained volatile. A rebound in European energy shares and greater political stability in Greece boosted European bourses. Stocks in Moscow also gained, with the dollar-traded up almost 7 percent following news that oil firm Rosneft had paid...

  • Gilead falls as Express Scripts picks AbbVie treatment. Express Scripts, the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment. "That is very specific to Gilead, so that one is getting crushed, but it shouldn't necessarily set...

  • Dec 22- The nation's largest pharmacy benefit manager has lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc treatments, Express Scripts said on Monday. Express Scripts has opposed the $84,000 pricetag of Gilead Sciences' Sovaldi treatment since it was approved a year...

  • Early Glance: Biotechnology companies Monday, 22 Dec 2014 | 10:22 AM ET

    Amgen Inc. fell $3.09 or 1.8 percent, to $167.08. Biogen Idec fell $8.52 or 2.4 percent, to $352.15. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • *Gilead falls as Express Scripts picks AbbVie treatment. NEW YORK, Dec 22- U.S. stocks were modestly higher on Monday, after the benchmark S&P 500 notched its best weekly performance in nearly two months, as a sharp drop in Gilead Sciences reined in broader gains. Express Scripts, the nation's largest pharmacy benefit manager, has lined up a cheaper price from AbbVie...

  • NEW YORK, Dec 22- U.S. stocks opened modestly higher on Monday, after the benchmark S&P 500 notched its best weekly performance in nearly two months, but a sharp drop in Gilead Sciences weighed on the market.

  • *Gilead falls as Express Scripts picks AbbVie treatment. Brent last traded down 26 cents at $61.12 while U.S. crude was last off 0.6 percent at $56.77 after Saudi Arabia indicated it could increase its output. "Oil is in the process of bottoming out here," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.

  • *Gilead falls as Express Scripts chooses AbbVie treatment. NEW YORK, Dec 22- U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, ahead of data on the housing market. Brent last traded down 21 cents at $61.17 while U.S. crude was last off 0.7 percent at $56.74 after Saudi Arabia indicated it could...

  • Express Scripts Holding Co. said Monday it will no longer cover Sovaldi and Harvoni from Gilead Sciences Inc. or Johnson& Johnson's Olysio starting Jan. 1, except under limited circumstances. Express Scripts will still cover the other drugs if patients have already started treatment or if the patient has a clinical exception and needs those particular drugs.

  • Dec 22- Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies. The first study, testing a combination of 50 mg of Achillion's ACH-3102 and 400 mg of Gilead Sciences Inc's Sovaldi, showed the regimen sustained a cure in patients for four weeks...

  • US STOCKS-Futures climb after three-day run Monday, 22 Dec 2014 | 7:45 AM ET

    *Gilead falls as Express Scripts chooses AbbVie treatment. NEW YORK, Dec 22- U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, as oil prices continued to show signs of stabilizing. However, Brent pulled back to last trade down 14 cents to $61.24 while U.S. crude was last off 0.4 percent at $56.91.

  • Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading. The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline...

  • US stock indexes drift higher in midday trading Monday, 22 Dec 2014 | 2:13 AM ET

    U.S. financial markets drifted slightly higher in midday trading Monday, although the gains were held back by discouraging data on U.S. home sales and a deepening slide in oil prices. KEEPING SCORE: The Dow Jones industrial average rose 87 points, or 0.5 percent, to 17,893 as of 12:06 p.m. Eastern time. THE QUOTE: "With the Dow being up substantially more than the S&P...

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12- week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences. AbbVie's newly approved regimen is also less costly than Gilead's newest one-pill regimen that combines Sovaldi with...

  • Final Glance: Biotechnology companies Friday, 19 Dec 2014 | 6:41 PM ET

    Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.

  • FDA approves AbbVie combo hepatitis C treatment Friday, 19 Dec 2014 | 3:35 PM ET

    TRENTON, N.J.— Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie. The Food and Drug Administration on Friday approved the sale of a packaged treatment called Viekira Pak made by AbbVie Inc. of North Chicago, Illinois. It includes a combination pill, which...

  • Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.

  • Midday Glance: Biotechnology companies Friday, 19 Dec 2014 | 1:25 PM ET

    Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.

  • Most active Nasdaq-traded stocks Friday, 19 Dec 2014 | 1:25 PM ET

    American Realty Capital Properties Inc. fell. 6 percent to $8.02 with 28,386,500 shares traded. Apple Inc. fell. 8 percent to $111.78 with 75,717,300 shares traded. BlackBerry Ltd. fell. 8 percent to $9.99 with 30,981,500 shares traded.

  • Early Glance: Biotechnology companies Friday, 19 Dec 2014 | 10:20 AM ET

    Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.